YieldMax MSTR Option Income Strategy ETF (MSTY) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- Income / Options OverlaySector
- $87.7552W High
- $11.5552W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track YieldMax MSTR Option Income Strategy ETF (MSTY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, YieldMax MSTR Option Income Strategy ETF has traded between a low of $11.55 and a high of $87.75, highlighting its annual price range. Buy and sell YieldMax MSTR Option Income Strategy ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Most Recent News
Workday launches AI research team with new innovations amid mixed analyst ratings.
Workday has established a dedicated AI Research team to develop advanced, reliable AI solutions for enterprises, achieving notable improvements in AI memory precision and task accuracy. The company also introduced a PhD Fellowship program to support ...

Sea Limited director sells 20,000 shares worth $2.4 million
Heng Chen Seng, a director at Sea Limited, sold 20,000 shares valued at $2.4 million. This insider sale may indicate personal portfolio adjustments but does not necessarily reflect company performance. Investors should monitor further insider activit...

Moderna shares soar over 160% after positive Phase 3 melanoma vaccine trial results
Moderna and Merck announced successful Phase 3 trial results for their personalized mRNA melanoma vaccine combined with Keytruda, showing significant improvement in recurrence-free and distant metastasis-free survival. This marks the first positive l...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.